Marstacimab-Hncq (1 brand name, 1 dosage form, 1 route)
Available dosage forms: INJECTABLE.
Routes of administration: SUBCUTANEOUS.
Brand Names
- HYMPAVZI
Indications and Usage
HYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 6 years of age and older with: •hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors, or •hemophilia B (congenital factor IX deficiency) with or without factor IX inhibitors.
Contraindications
None.
Adverse Reactions
The following clinically significant adverse reactions are described elsewhere in the labeling: •Thromboembolic Events [see Warnings and Precautions (5.1)] •Hypersensitivity [see Warnings and Precautions (5.2)]
Drug Interactions
Partial Thromboplastin Time (aPTT) and Prothrombin Time (PT) No clinically significant differences in standard measures of coagulation including activated partial thromboplastin time (aPTT) and prothrombin time (PT) were observed following marstacimab‑hncq therapy.
Mechanism of Action
Marstacimab‑hncq is a human monoclonal IgG1 antibody directed against the Kunitz domain 2 (K2) of TFPI to neutralize TFPI activity and enhance coagulation. TFPI is the primary inhibitor of the extrinsic coagulation cascade and negatively regulates thrombin generation within the extrinsic pathway of coagulation by inactivating the protease functions of FXa/FVIIa/TF complex. TFPI binds to and inhibits the factor Xa active site via its second Kunitz inhibitor domain (K2).
Overdosage
Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for overdose management recommendations.